MedTrace Logo

Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali

NCT02784743 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1139

Last updated 2016-05-27

No results posted yet for this study

Summary

Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date and most of them are more than 15 years old. To address this issue in April 2000, the investigators started studies to update the epidemiology of lymphatic filariasis. There is no ongoing lymphatic filariasis control program in 2000 in Mali in terms of preventive chemotherapy treatment or vector control.

To fill these gaps, this current study aims to assess the impact of albendazole-ivermectin combination treatment on Wuchereria bancrofti infection and transmission in 6 rural highly endemic villages of Mali.

Conditions

  • Lymphatic Filariasis

Interventions

DRUG

''albendazole'' and ''ivermectin''

annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)

Sponsors & Collaborators

  • Malaria Research and Training Center, Bamako, Mali

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • Centre d'Appui à la lutte contre la Maladie

    lead OTHER

Principal Investigators

  • Sékou F Traoré, PhD · Malaria Research and Training Center, Mali

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2008-12-31
Completion
2015-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784743 on ClinicalTrials.gov